Streetbeat News

Analyst Ratings

PFGC

Morgan Stanley analyst John Glass has maintained an Equal-Weight rating on Performance Food Gr (NYSE:PFGC) and raised the price target from $65 to $68.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:32 pm

OLPX

Morgan Stanley analyst Dara Mohsenian has maintained an Equal-Weight rating on Olaplex Hldgs (NASDAQ:OLPX) but lowered the price target from $3.65 to $2.1.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:30 pm

ODD

Morgan Stanley analyst Dara Mohsenian has maintained an Equal-Weight rating on ODDITY Tech (NASDAQ:ODD) and lowered the price target from $57 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:29 pm

NYT

Morgan Stanley analyst Thomas Yeh has maintained an Equal-Weight rating on New York Times (NYSE:NYT) and raised the price target from $42 to $45.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:28 pm

MRVI

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:26 pm

LCID

Morgan Stanley analyst Adam Jonas has maintained an Underweight rating on Lucid Group (NASDAQ:LCID) and lowered the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:25 pm

DOOR

Stephens & Co. analyst Trey Grooms has downgraded Masonite International (NYSE:DOOR) from Overweight to Equal-Weight and lowered the price target from $130 to $93.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:24 pm

ARTL

Artelo Biosciences, Inc. (NASDAQ:ARTL) has announced new research demonstrating the protective properties of its clinical asset, ART27.13, against muscle degeneration caused by certain cancers. The research shows that ART27.13 not only increases appetite in cancer patients but also prevents muscle wasting. The company is currently evaluating ART27.13 in a Phase 2a clinical trial to determine its effect on lean body mass, weight gain, and improvement of anorexia in cancer patients.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:23 pm

RAMP

Morgan Stanley analyst Stan Zlotsky has maintained an Overweight rating on LiveRamp Holdings (NYSE:RAMP) and raised the price target from $37 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:22 pm

CDNA

Stephens & Co. analyst Mason Carrico has upgraded CareDx (NASDAQ:CDNA) from Equal-Weight to Overweight and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:20 pm